EBV viruksen ja Sars-2 koronaviruksen samanaikaisinfektio

1.  2021 Jan-Dec;9:23247096211040626.

doi: 10.1177/23247096211040626.

Epstein-Barr Virus Coinfection in COVID-19

Asim Nadeem  ¹ , Krithika Suresh  ¹ , Hassan Awais  ¹ , Saba Waseem  ¹

• PMCID: PMC8392798
• DOI: 10.1177/23247096211040626

Free PMC article

Abstract

Epstein-Barr virus (EBV), a member of the herpes virus family, is a causative agent for infectious mononucleosis in young adults. It has an asymptomatic and subclinical distribution in about 90% to 95% of the world population based on seropositivity. EBV is associated with various lymphomas, nasopharyngeal carcinoma, and in immunocompromised states can give rise to aggressive lymphoproliferative disorders. Symptomatic patients mostly present with mild hepatitis, rash, oral symptoms, lymphadenopathy, and generalized malaise.

 Recently with the COVID-19 (coronavirus disease-2019) pandemic, hepatitis has been found to be related to acute EBV and cytomegalovirus  (CMV) reactivation versus acute infection in the absence of other major causes. We describe a case of EBV coinfection in a patient with resolving mild COVID-19 infection.

Keywords: COVID-19; EBV; hepatitis. 

 

2.

  https://pubmed.ncbi.nlm.nih.gov/34791940/

 

. 2021 Nov 18;8850666211053990.

Reactivation of EBV and CMV in Severe COVID-19- Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients

Jan-Hendrik Naendrup et al. 

DOI: 10.1177/08850666211053990 

Conclusion: Critically ill patients with COVID-19 are at a high risk for EBV and CMV reactivations. Whether these reactivations are a cause of hyperinflammation and require targeted treatment remains uncertain. However, in patients with clinical deterioration or signs of hyperinflammation targeted treatment might be beneficial and warrants further studying.